Literature DB >> 16832849

Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus.

Erika R Chang1, Christian A Pineau, Sasha Bernatsky, Carolyn Neville, Ann E Clarke, Paul R Fortin.   

Abstract

OBJECTIVE: We describe the pattern of incidence of thrombovascular events after diagnosis of systemic lupus erythematosus (SLE) in a cohort of lupus patients.
METHODS: Descriptive study of prospectively collected data using incidence rates of thrombovascular events and 95% confidence intervals (CI) calculated for predetermined periods of observation. Kaplan-Meier survival curves were plotted to estimate thrombovascular event-free survival.
RESULTS: Among 426 individuals, person-years contributed were as follows: 399 persons and 4356.0 person-years for all events; 417 persons and 4691.9 person-years for arterial events; and 408 persons and 4846.6 person-years for venous events. The incidence of thrombovascular events was highest during the first year after SLE diagnosis (4.00, 95% CI 2.24-6.59) and after 20 years (ranging from 3.32, 95% CI 1.52-6.30, to 4.99, 95% CI 0.60-18.01), and was lowest between 1 and 5 years after SLE diagnosis (1.00, 95% CI 0.53-1.72). A similar pattern was observed for arterial events, while venous events showed a higher incidence rate only in the first 30 days after SLE diagnosis (12.06, 95% CI 3.29-30.87) and remained low afterwards. The probabilities of remaining event-free at 5, 10, and 15 years were as follows: 0.92, 0.85, and 0.78, respectively, for all thrombovascular events; 0.95, 0.88, and 0.82, respectively, for arterial events; and 0.98, 0.95, and 0.94, respectively, for venous events.
CONCLUSION: Thrombovascular events occur throughout the course of lupus, with the highest risk of arterial or venous events in the first year after diagnosis, and the pattern of occurrence varying thereafter.

Entities:  

Mesh:

Year:  2006        PMID: 16832849

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

1.  Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees.

Authors:  Hussain R Yusuf; W Craig Hooper; Scott D Grosse; Christopher S Parker; Sheree L Boulet; Thomas L Ortel
Journal:  Thromb Res       Date:  2014-10-22       Impact factor: 3.944

2.  Autoimmune diseases and venous thromboembolism: a review of the literature.

Authors:  Bengt Zöller; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

3.  Genetic risk factors for thrombosis in systemic lupus erythematosus.

Authors:  Rachel Kaiser; Yonghong Li; Monica Chang; Joseph Catanese; Ann B Begovich; Elizabeth E Brown; Jeffrey C Edberg; Gerald McGwin; Graciela S Alarcón; Rosalind Ramsey-Goldman; John D Reveille; Luis M Vilá; Michelle A Petri; Robert P Kimberly; Kimberly E Taylor; Lindsey A Criswell
Journal:  J Rheumatol       Date:  2012-06-15       Impact factor: 4.666

Review 4.  Postoperative risk of venous thromboembolism in rheumatic disease patients.

Authors:  Lauren E Wong; Anne R Bass
Journal:  Curr Rheumatol Rep       Date:  2015-02       Impact factor: 4.592

5.  Factors associated with arterial vascular events in PROFILE: a Multiethnic Lupus Cohort.

Authors:  A M Bertoli; L M Vilá; G S Alarcón; G McGwin; J C Edberg; M Petri; R Ramsey-Goldman; J D Reveille; R P Kimberly
Journal:  Lupus       Date:  2009-10       Impact factor: 2.911

6.  The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based study.

Authors:  J Antonio Aviña-Zubieta; Kateryna Vostretsova; Mary A De Vera; Eric C Sayre; Hyon K Choi
Journal:  Semin Arthritis Rheum       Date:  2015-05-19       Impact factor: 5.532

7.  Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus.

Authors:  Chi Chiu Mok; Ling Yin Ho; Ka Lung Yu; Chi Hung To
Journal:  Clin Rheumatol       Date:  2010-01-26       Impact factor: 2.980

8.  A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases.

Authors:  Jason J Lee; Janet E Pope
Journal:  Arthritis Res Ther       Date:  2014-09-25       Impact factor: 5.156

9.  Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry.

Authors:  Antonio Fernández-Nebro; Íñigo Rúa-Figueroa; Francisco J López-Longo; María Galindo-Izquierdo; Jaime Calvo-Alén; Alejandro Olivé-Marqués; Carmen Ordóñez-Cañizares; María A Martín-Martínez; Ricardo Blanco; Rafael Melero-González; Jesús Ibáñez-Rúan; José Antonio Bernal-Vidal; Eva Tomero-Muriel; Esther Uriarte-Isacelaya; Loreto Horcada-Rubio; Mercedes Freire-González; Javier Narváez; Alina L Boteanu; Gregorio Santos-Soler; José L Andreu; José M Pego-Reigosa
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.817

10.  Antiphospholipid antibodies in patients with upper-extremity deep vein thrombosis.

Authors:  Milena K Nikolova-Vlahova; Krasimir V Nikolov; Marta P Baleva; Alexey S Savov
Journal:  Cent Eur J Immunol       Date:  2015-10-15       Impact factor: 2.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.